Item 1.01 Entry into Material Definitive Agreement.

On September 3, 2021, THC Therapeutics, Inc. (the "Company") and Shefford Capital Partners, LLC, a Delaware limited liability company (the "Investor"), entered into a Securities Purchase Agreement (the "Purchase Agreement") pursuant to which (i) the Investor agreed to purchase from the Company $25,000,000 of the Company's restricted common stock (the "Stock") at future closings during a three-year term, and (ii) the Investor agreed to arrange a $25,000,000 traditional debt facility for the Company to position the Company with a 1:1 debt-to-equity ratio.

The proceeds of each closing can only be used to acquire businesses in or related to the marijuana and psychedelic industries, or other modern healthcare-related industries, and the Investor is required to approve each acquisition (each an "Acquisition"). The purchase price for the common stock at each closing will be closing price of the Company's common stock on the date immediately preceding the earlier of the closing of each Acquisition, or the announcement of that Acquisition.

The obligation of the Investor to purchase Stock pursuant to the Purchase Agreement is subject to several conditions, including (i) that the Company shall have delivered a draw-down notice to the Investor, (ii) that the Investor shall have approved the Acquisition in connection with a closing, (iii) that the representations and warranties in the Purchase Agreement shall be true and correct in all material respects, (iv) that no event shall have occurred which could reasonably be expected to have a material adverse effect on the Company, (v) that the Company's common stock shall continue to be quoted on the OTC Link ATS (or a replacement quotation system), and (iv) that trading in the Company's common stock shall not have been suspended.

The foregoing description of the Purchase Agreement is qualified in its entirety by the full text of the Purchase Agreement, which is filed as Exhibit 10.1 to, and incorporated by reference in, this report.

Item 3.02 Unregistered Sales of Equity Securities.

The information in Item 1.01 above is incorporated by reference into this Item 3.02. The Company will be selling the Stock to the Investor in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder, as there has been and will be no general solicitation in connection with the offering to the Investor, the Investor is an accredited investor, and the transaction will not involve a public offering.

Item 9.01 Financial Statements and Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.





Exhibit No.   Description
  10.1*         Securities Purchase Agreement, by and between THC Therapeutics,
              Inc., and Shefford Capital Partners, LLC, dated September 1, 2021

* Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or Exhibit so furnished.






2

© Edgar Online, source Glimpses